Koshinski Asset Management
AXDX icon

Koshinski Asset Management’s Accelerate Diagnostics AXDX Stock Holding History

Koshinski Asset Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5
Closed -$292 – 2156
2021
Q3 		$292 Buy
+5
New +$326 ﹤0.01% 2146

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Koshinski Asset Management's AXDX Position: Q4 2021 in Review

Koshinski Asset Management sold out of Accelerate Diagnostics (AXDX) in Q4 2021, closing a stake of 5 shares — an estimated $292 sold.

Koshinski Asset Management first reported a position in AXDX in Q3 2021 and held it in 1 quarter. The position peaked at $292 in Q3 2021. 107 funds tracked by Wall St. Rank hold AXDX as of Q4 2021.

  • Koshinski Asset Management reported no remaining Accelerate Diagnostics position as of Q4 2021 after selling out during the quarter.
  • Koshinski Asset Management sold 5 Accelerate Diagnostics shares in Q4 2021, an estimated $292.
  • Koshinski Asset Management first reported a position in Accelerate Diagnostics in Q3 2021 and held it in 1 quarter.
  • Koshinski Asset Management's Accelerate Diagnostics position peaked at $292 in Q3 2021.
  • 107 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q4 2021.

Based on Koshinski Asset Management's 13F filing for Q4 2021, filed 14 Jan 2022.